TickerGraveyard
TickerGraveyard

C1559356

Taken Private
Biostax Corp.

C1559356 — Post-Mortem

Biostax Corp., founded in Florida, focused on biopharmaceuticals aiming to provide affordable healthcare solutions targeting immune restoration. The company peaked in operational scope with aspirations tied to its lead drug candidate, JKB-122, intended for autoimmune conditions and fibrosis. However, by February 19, 2025, Biostax faced financial constraints, reporting total assets of approximately $6.669 million, substantially below the $10 million threshold required for continued public listing. On this date, the company notified the SEC of its decision to voluntarily delist its common stock from the OTC Pink marketplace, following a shareholder vote wherein 76.4% of shareholders indicated support. This delisting decision was deemed necessary to reduce operating costs and redirect focus,,

Biostax Corp. voluntarily delisted its common stock from the OTC Pink marketplace on February 19, 2025, due to low asset levels and cost considerations associated with public reporting.

Could I Have Seen This Coming?

No structured pre-delisting signals found in our records. Absence of signals does not imply absence of risk.

Post-Mortem Analysis

Five-section narrative grounded in primary filings and contemporaneous reporting.

Origin

Biostax was incorporated to offer solutions in immune restoration, but its operational trajectory was hampered by financial constraints and a narrow asset base.

Peak

The company reached an operational peak with ambitions for extensive drug development, notably relating to its product pipeline including JKB-122.

Turning Point

The decisive turning point occurred when the Board recognized that the costs of remaining a reporting company outweighed perceived benefits, culminating in a significant shareholder vote favoring delisting.

End

Biostax Corp. effectively ceased trading on public markets following the submission of Form 25 on February 19, 2025, leading to a suspension of reporting obligations under the Exchange Act.

Impact

The voluntary delisting has eliminated the ability for public trading, impacting liquidity for shareholders and potentially reducing future access to capital markets.

Lessons for Today's Investors

Transferable patterns identified from this case, written as research-report observations.

  1. 1

    Investors should assess a company's asset levels relative to listing requirements, as financial health is critical for maintaining a public listing.

  2. 2

    Board decisions regarding public company status should be guided by comprehensive cost-benefit analyses reflecting the broader market context.

  3. 3

    Shareholder engagement and consent are vital; major decisions often depend on overwhelming support from the investor base.

Frequently Asked Questions

Why did Biostax Corp. choose to delist its stock?
Biostax Corp. decided to voluntarily delist due to the high costs of remaining a public company and the financial impracticality stemming from asset levels below $10 million.
What were Biostax's total assets reported prior to delisting?
As of November 20, 2024, Biostax Corp. reported total assets of approximately $6.669 million.
What percentage of shareholders supported the delisting?
76.4% of shareholders supported the decision to delist and deregister the company's stock.

Source Filings

Every fact on this page is anchored to a primary SEC filing or regulatory record. Open any source to verify against the original document.

Narrative sections on this page are AI-assisted summaries of the filings linked above. All content is reviewed against primary sources; if you find an error, the canonical record is always the linked filing.

Industries:

Tags:

Related tickers:

Share: